GENESIS-PHARMA
GENESIS Pharma, a leading regional biopharma company operating in Europe, and Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, announce an exclusive distribution agreement for RIPRETINIB in 14 European markets in Central and Eastern Europe. Under the terms of the agreement, GENESIS Pharma will exclusively commercialize RIPRETINIB for the treatment of fourth-line gastrointestinal stromal tumor (GIST) in: Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Greece, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia, and Slovenia.
RIPRETINIB is approved in the European Union for the treatment of adult patients with advanced gastrointestinal stromal tumour (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib.
Ms. Margarida Duarte, Senior Vice President, Head of International, Deciphera Pharmaceuticals stated: “We are excited to partner with GENESIS Pharma to distribute RIPRETINIB across Central and Eastern Europe, ensuring fourth-line GIST patients in these countries have access to this standard-of-care treatment. Deciphera is committed to commercializing RIPRETINIB globally, and our agreement with GENESIS Pharma builds upon the significant progress we have already made launching the therapy in Europe, positioning us well for continued growth as we work together to improve the lives of GIST patients”.
Mr. Constantinos Evripides, Managing Director of GENESIS Pharma stated: “We are pleased to expand the network of our international partners and honored that Deciphera recognized our expertise and track record in the commercialization of innovative biopharmaceutical products targeting severe and rare diseases. This agreement is an important step forward in expanding our geographical reach and delivering our mission to ensure that such products are made available to patients in the countries we operate. We look forward to joining forces with Deciphera to enable access to this important innovative therapy for eligible patients in Central and Eastern Europe”.
About Gastrointestinal stromal tumor (GIST)
Gastrointestinal stromal tumor (GIST) is a rare neoplasm of the gastrointestinal tract affecting the digestive tract or nearby structures within the abdomen, most often presenting in the stomach or small intestine1. GIST is the most frequent sarcoma of the gastrointestinal tract, with a reported incidence of 10-15 cases per million per year2. The majority of GISTs are driven by two oncogenic protein kinases, KIT and PDGFRA gain-of-function mutations. The most common primary mutations are in KIT kinase, representing approximately 80% of cases, or in PDGFRA kinase, representing approximately 5-10% of cases3. Current therapies are unable to inhibit the full spectrum of primary and secondary mutations, which drives resistance to most tyrosine kinase inhibitors (TKIs) therefore leading to disease progression4. Estimates for 5-year survival rate range from 48% to 90%, depending on the stage of the disease at diagnosis5.
About Deciphera
Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, RIPRETINIB is Deciphera’s switch-control inhibitor for the treatment of fourth-line GIST. RIPRETINIB is approved in Australia, Canada, China, the European Union, Hong Kong, Iceland, Israel, Liechtenstein, Macau, New Zealand, Singapore, Switzerland, Taiwan, the United Kingdom, and the United States. For more information, visit www.deciphera.com and follow us on LinkedIn and X (@Deciphera).
About GENESIS Pharma
GENESIS Pharma is a regional biopharma company focused on the commercialization of innovative biopharmaceutical products targeting severe and rare diseases in Central and Eastern Europe. Established in 1997, GENESIS Pharma was among the first pharmaceutical companies in Europe to specialize in the marketing, sales and distribution of biopharmaceutical products. GENESIS Pharma maintains a strong portfolio in therapeutic areas with high unmet medical need through long standing strategic alliances with some of the leading global biopharma companies. For more information, please visit www.genesispharmagroup.com.
1. Parab TM, DeRogatis MJ, Boaz AM, Grasso SA, Issack PS, Duarte DA, Urayeneza O, Vahdat S, Qiao JH, Hinika GS. Gastrointestinal stromal tumors: a comprehensive review. J Gastrointest Oncol. 2019 Feb;10(1):144-154.
2. Søreide K, Sandvik OM, Søreide JA, Giljaca V, Jureckova A, Bulusu VR. Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies. Cancer Epidemiol. 2016 Feb;40:39-46.
3. Lostes-Bardaji MJ, García-Illescas D, Valverde C, Serrano C. Ripretinib in gastrointestinal stromal tumor: the long-awaited step forward. Ther Adv Med Oncol. 2021 Jan 7;13:1758835920986498.
4. Gajiwala KS, Wu JC, Christensen J, Deshmukh GD, Diehl W, DiNitto JP, English JM, Greig MJ, He YA, Jacques SL, Lunney EA, McTigue M, Molina D, Quenzer T, Wells PA, Yu X, Zhang Y, Zou A, Emmett MR, Marshall AG, Zhang HM, Demetri GD. KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients. Proc Natl Acad Sci U S A. 2009 Feb 3;106(5):1542-7.
5. American Cancer Society. (March 1, 2023). Gastrointestinal stromal tumor survival rates. Retrieved December 21, 2023, from https://www.cancer.org/cancer/types/gastrointestinal-stromal-tumor/detection-diagnosis-staging/survival-rates.html.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240111379909/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LumRisk Announces Strategic Reset and USD 5 Million Capital Commitment to Accelerate Its Transformation Toward an AI-Driven QIS and Multi-Asset Platform3.12.2025 11:30:00 CET | Press release
LumRisk today announced a major milestone in its evolution, with the approval and implementation of a comprehensive corporate reset. This includes the restructuring of legacy obligations and the reinforcement of the company’s balance sheet. These measures establish a strong foundation for a new phase of accelerated global growth across LumRisk’s core domains: Quantitative Investment Strategies (QIS) and Multi-Asset Analytics. As part of this strategic renewal, LumRisk has secured shareholder approval for a USD 5 million equity commitment, subject to customary conditions. This capital is intended to be deployed to scale the company’s next-generation platform, reinforce its data and technology capabilities, and deepen its offering across the global QIS ecosystem. In parallel, LumRisk is implementing a new management-led corporate structure, under which the leadership team will assume full operational control and a majority equity position upon finalisation of the process. This realignmen
Reply Awarded a 2025 AWS Partner of the Year Award3.12.2025 10:00:00 CET | Press release
Reply recognized as winner for EMEA Partner of the Year, Industry Energy & Utilities, one of many AWS Partners around the globe that help their customers drive innovation Reply [EXM, STAR: REY] is pleased to announce it is a recipient of a 2025 Geography and Global AWS Partner Award, recognizing leaders around the globe that are playing key roles in helping their customers drive innovation and build solutions on Amazon Web Services (AWS). Reply has been named the winner of the EMEA Partner of the Year – Industry Energy & Utilities award, which recognizes top AWS Partners with the AWS Energy Competency, which help customers build and implement advanced solutions powered by AWS across the industry value chain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251203089630/en/ Through its specialized companies — including Airwalk Reply, Comsysto Reply, Data Reply, Sense Reply, and Storm Reply — Reply leverages AWS capabilities to
FiRa Consortium Unveils FiRa Core 4.0 Specifications and Certification Program3.12.2025 10:00:00 CET | Press release
Featuring UL-TDoA, Aliro UWB updates, and expanded certification The FiRa® Consortium announces the release of its Core 4.0 Specifications and Certification Program, notable milestones in ultra-wideband (UWB) technology development. These updates complete the work of IEEE 802.15.4-2024 features to fulfill FiRa-defined use cases. They also enhance FiRa’s capabilities, enabling seamless interoperability and unlocking new possibilities for precise and secure ranging and positioning in diverse applications. Features of the FiRa Core 4.0 Specifications and Certification Program The FiRa Core 4.0 Specifications include updates that support expanded functionality and continued ecosystem growth. UL-TDoA – This feature enables the tracking of assets (UL-TDoA tags) by an infrastructure made of UL-TDoA anchors. The design ensures interoperability between the tags and the infrastructure, which optimizes tag simplicity and power consumption. The flexible design allows easy and customized deployment
Infobip Reports Record Black Friday Interactions as Retailers Accelerate Shift to Richer Customer Experiences3.12.2025 10:00:00 CET | Press release
Black Friday interactions grow by 15% year-on-year, marking a new milestone for Infobip’s global communications platform Infobip, the leading global cloud communications platform for customer engagement, identified a remarkable upswing in its Black Friday messaging traffic, with use of Rich Communication Services (RCS) surging 277% on Black Friday 2025 compared to the previous year. Email also remained a strong channel of choice among both retailers and consumers, showing an impressive 241% year-on-year increase, signaling that promotional and transactional communications continue to drive engagement during shopping peaks. Black Friday is no longer just a single day. The search for attractive deals extends beyond Friday, with consumers from around the globe seeking products, better price offers, and reliable, easy communication channels to connect with their favourite brands. Infobip identified significant increases in interactions not only in North America, but also in other key regio
Ramify Partners with ROYC to Enrich its Private Markets OfferUnder Its Own Brand3.12.2025 10:00:00 CET | Press release
ROYC, the market-leading European B2B platform for sourcing, structuring, and distributing private-market investments, and Ramify, the next-generation private wealth management platform based in France, today announced a strategic collaboration enabling Ramify to broaden its private-markets offering through a curated range of high-quality private-market funds and programs. The partnership enables Ramify to distribute, and scale modern private-markets programs under its own brand. Bringing a curated private-markets program suite to individual investors Through the collaboration, Ramify integrates a selection of highly sought-after, institutional-grade private-markets funds distributed through Luxembourg life-insurance wrappers. These funds can be invested into individually or as part of broader private-markets investment programs, including diversified and single-strategy vehicles across private equity, private credit, infrastructure and real assets - mirroring formats traditionally res
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom